Progenics Pharmaceuticals Reports Top Line Phase 3 Data For Prostate Cancer Imaging Agent 1404 | Latest News RSS feed

Progenics Pharmaceuticals Reports Top Line Phase 3 Data For Prostate Cancer Imaging Agent 1404 - Latest News


Progenics Pharmaceuticals Reports Top Line Phase 3 Data for Prostate Cancer Imaging Agent 1404

NEW YORK, Sept. 12, 2018 (GLOBE NEWSWIRE) — Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treatin... read more

Progenics Pharma's Stock Down on Dismal Phase III Study Data

Shares of Progenics Pharmaceuticals, Inc. PGNX have declined 12.1% since the close of trading on Sep 12, following the announcement of unsatisfactory data from a phase III study evaluating its imaging ... read more

Progenics: What Is The Value Of The Imaging Pipeline?

1404, the lead candidate for imaging prostate cancer, completed Phase 3 trial enrollment in January 2018; top-line data is expected in Q3 2018 ... Last month, we discussed the Q1 earnings report of Pr... read more

Looking for another news?


Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404Top-line Data Expected in 3Q2018

NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals ... cancer, today announced that it has completed enrollment in its Phase 3 study of 1404, a PSMA-targeted small molecule SPECT/CT ... read more


Why Progenics Shares Are Getting Crushed

Progenics Pharmaceuticals ... results from its prostate cancer study. Specifically, the firm announced top-line data from its Phase 3 study of 1404, its prostate specific membrane antigen-targeted sma... read more

Top-line Data Expected in 4Q2018

We look forward to reporting top-line data from the trial in the fourth quarter of 2018 while initiating a second Phase 3 ... PSMA-targeted imaging agents for prostate cancer (1404 and PyL™), and 3) i... read more

Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer

PyL is the Company’s PSMA-targeted small molecule PET imaging agent designed to visualize prostate cancer ... Progenics. “Our data from OSPREY provides strong rationale for continued development, and ... read more

Global Prostate Cancer Therapeutics Industry

NEW YORK, Feb. 6, 2019 /PRNewswire/ -- This report analyzes the worldwide markets for Prostate Cancer Therapeutics ... by Astellas Pharma for Review Progenics Pharmaceuticals Begins Phase 3 Clinical T... read more

Today’s Research Reports on Stocks to Watch: AbbVie and Progenics Pharmaceuticals

RDI Initiates Coverage on: AbbVie Inc. https://www.rdinvesting.com/report/?ticker=ABBV Progenics Pharmaceuticals ... reporting concerning top-line data for the phase 3 clinical trial testing of its pr... read more

Progenics Pharmaceuticals Reports Top Line Phase 3 Data for Prostate Cancer Imaging Agent 1404

NEW YORK, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treati... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us